COVID-19

Curated collection of publications from JITC  

JITC is committed to disseminating the most current COVID-19 and other coronavirus-related information and research to the oncology community and public at a rapid pace. Articles in this collection will be updated on a regular basis as they reach publication in the journal. To search for other content of interest within the journal, visit jitc.bmj.com.

• Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis (29 Nov 2021)
• Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations (30 April 2021)
• Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score (22 March 2021)
• SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study (16 Feb 2021)
• COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report (11 Feb 2021)
• Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (19 Jan 2021)
• Management of immune checkpoint therapy for patients with cancer in the face of COVID-19 (10 Dec 2020)
• Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management (20 Nov 2020)
• Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey (16 Oct 2020)
• Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists (15 Oct 2020)
• A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study (6 Sept 2020)
• Outcomes and biomarker analyses among COVID-19 patients treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy (11 Aug 2020)
• SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity (29 July 2020)
• Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment (21 July 2020)
• ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-COV-2 COVID-19 (16 July 2020)
• BCG vaccine and COVID-19: Implications for infection prophylaxis and cancerimmunotherapy (6 July 2020)
• On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19 (1 July 2020)
• Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management (18 June 2020)
• Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy (19 May 2020)
• COVID-19 and lung cancer: risks, mechanisms and treatment interactions (19 May 2020)
• COVID-19 and immune checkpoint inhibitors: initial considerations (19 May 2020)
• The Society for Immunotherapy of Cancer perspective on regulation of interleukin 6 signaling in COVID-19-related systemic inflammatory response (7 May 2020)
• Insights from immuno-oncology: The Society for Immunotherapy of Cancer statement on access to IL-6-targeting therapies for COVID-19 (16 April 2020)

Please continue to check back for updated content. For additional COVID-19 resources and discussion forums, visit SITC’s COVID-19 Resources page.